NeuroQuest

NeuroQuest Overview

NeuroQuest has developed NeuroScreen™, a novel blood-based diagnostic test for Alzheimer's disease (AD). The technology is based on the specific response of the immune system to a amyloid-beta accumulation. The company's propriety technology is based on the award-winning research of Professor Michal Schwartz of the Weizmann Institute of Science. NeuroQuest has licensed the intellectual property covering this technology from Yeda (the Technology Transfer Company of the Weizmann Institute of Science) and holds an exclusive global license for its development and commercialization. NeuroQuest has established a US subsidiary and clinical development center in Charleston, South Carolina with the assistance and financial support of the South Carolina Research Authority (SCRA). They are working with Vikor Scientific, a CLIA-certified lab, to provide the data required for FDA approval, and with Pentara Corporation for data analysis.

Cumulative Funding Raised Over Time ($)

Latest News

Nov 15, 2022 · www.biospace.com

growth-positive

Collaborative Study by NeuroQuest and AIBL Shows Specific Biomarkers for Alzheimer's Could Lead to Blood-based Screening Tool

NeuroQuest, a company focused on the discovery of blood-based immune biomarkers in pre-clinical stage Alzheimers, has completed a clinical study with the Australian Imaging, Biomarker & Lifestyle Flagship Study (AIBL). The study demonstrated that specific immune deficits associated with the development of Alzheimers disease may be identified. The results of the study were published in Alzheimers & Dementia: The Journal of the Alzheimers Association. The study presents information on specific biomarkers that can become a low cost, practical, blood-based screening tool with 95% sensitivity and 83% specificity to identify subjects who have Beta Amyloid plaques, which are associated with Alzheimers disease, in their brains.

Partners

Nov 9, 2022 · alz-journals.onlinelibrary.wiley.com

Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease

May 15, 2014 · www.charlestondigitalcorridor.com

growth-positive

Israeli-based NeuroQuest Receives SCRA Technology Ventures Funding

SCRA Technology Ventures has closed two rounds of funding on its first Israeli investment, NeuroQuest, an Israeli biotech company. NeuroQuest has developed immune-based biomarkers for ALS and Alzheimers disease. The investment was made through a collaboration between South Carolina business leaders and Israeli companies. The funding was led by InterTech Group and the Maryland/Israel Trendlines Fund. NeuroQuest will establish its clinical development center in South Carolina.

Investment

Jan 28, 2013 · nocamels.com

growth-positive

NeuroQuest: Detecting Alzheimer's Before Symptoms Appear

Israeli company NeuroQuest is developing a new method of testing for neurodegenerative diseases, such as Alzheimers, based on the measurement of immune biomarkers in the patients bloodstream. The technology has shown up to 85% diagnostic accuracy in clinical trials. NeuroQuest has received a $500,000 investment from InterTech Group and Maryland/Israel Trendlines Fund. The company aims to set up a marketable diagnostic test for Alzheimers disease and hopes to encourage pharmaceutical companies to develop more effective treatments. NeuroQuest plans to expand the use of the immune biomarker method to other neurodegenerative diseases in the future.

Customers

Funding

Team Members

8

Employees: 1-10

Web & Social Links

Locations

Misgav Regional Council, Tchelet Street 17, Israel

Charleston, SC, USA

Photos & Videos

1 item(s)

NeuroQuest Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info